{"title":"FDA expands Zytiga's use for late-stage prostate cancer","authors":"From Ora Staff Reports","doi":"10.1097/01.cot.0000426461.21453.1c","DOIUrl":null,"url":null,"abstract":"FDA expanded the approved use of abiraterone acetate (Zytiga, Jannsen Bioech) to treat men with late-stage castration-resistant prostate cancer prior to receiving chemotherapy.","PeriodicalId":12354,"journal":{"name":"Formulary","volume":"4 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2012-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Formulary","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/01.cot.0000426461.21453.1c","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
Abstract
FDA expanded the approved use of abiraterone acetate (Zytiga, Jannsen Bioech) to treat men with late-stage castration-resistant prostate cancer prior to receiving chemotherapy.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
